Features | Partner Sites | Information | LinkXpress
Sign In
JIB
GLOBETECH PUBLISHING
GLOBETECH PUBLISHING

Nanoparticle Created for Cancer Therapy

By BiotechDaily International staff writers
Posted on 29 Apr 2014
Image: X-ray destruction of human breast cancer cells using Cu-Cy particles. The images show the live cancer cells stained green and the dead cells stained red (Photo courtesy of Wei Chen/UT Arlington).
Image: X-ray destruction of human breast cancer cells using Cu-Cy particles. The images show the live cancer cells stained green and the dead cells stained red (Photo courtesy of Wei Chen/UT Arlington).
A physicist working to create a luminescent nanoparticle to use in security-related radiation detection may have instead developed a new tool for photodynamic cancer therapy.

Wei Chen, professor of physics and co-director of University of Texas (UT) at Arlington (USA) Center for Security Advances Via Applied Nanotechnology, was testing a copper-cysteamine (Cu-Cy) complex created in his lab when he discovered mysterious decreases in its luminescence, or light emitting power, over a time-lapse exposure to X-rays. Researching further, he discovered that the nanoparticles, called Cu-Cy, were losing energy as they emitted singlet oxygen—a toxic byproduct used to damage cancer cells in photodynamic therapy.

Because Prof. Chen also is leading federally funded cancer research, he knew he had found something unique. Testing revealed that the Cu-Cy nanoparticles, combined with X-ray exposure, significantly slowed tumor growth in lab studies. “This new idea is simpler and better than previous photodynamic therapy methods. You don’t need as many steps. This material alone can do the job,” Prof. Chen said. “It is the most promising thing we have found in these cancer studies and we’ve been looking at this for a long time.”

Prof. Chen’s research will be published in the August 2014 edition of the Journal of Biomedical Nanotechnology. The article was published online April 2014. The University has also filed a provisional patent application on the new complex.

Photodynamic therapy (PDT) harms cancer cells when a photosensitizer introduced into tumor tissue produces toxic singlet oxygen after being exposed to light. In some studies, this light exposure is done through use of visible or near-infrared lasers. Others have found more success by also introducing luminescent nanoparticles into the tumor. Researchers activate the luminescent nanoparticle with near-infrared light or X-rays, which in turn activates the photosensitizer.

Both techniques have limitations for treating deep tissue cancers. They are either ineffective or the light source needed to activate them does not penetrate deep enough. Prof. Chen reported that X-ray-inducible Cu-Cy particles surpass current photosensitizers because the X-rays can penetrate deep into tissue. Furthermore, Cu-Cy nanoparticles do not need other photosensitizes to be effective so the treatment is more convenient, efficient and cost-effective.

“Dr. Chen’s commitment to his work in cancer-related therapy, as well as his work in the area of homeland security, demonstrates the wide-ranging applications and great value of basic science research,” said Carolyn Cason, vice president for research at UT Arlington. “These advances have the potential to change the way some cancers are treated and make therapy more effective—a benefit that would be boundless.”

Prof, Chen’s team assessed the Cu-Cy on human breast and prostate cancer cells in the lab and found it to be an effective treatment when combined with X-ray exposure. In one esperiment, for example, a tumor treated with Cu-Cy injection and X-ray exposure stayed virtually the same size over a 13-day period while a tumor without the full treatment grew by three times.

Another benefit of the new nanoparticle is a low toxicity to healthy cells. Furthermore, Cu-Cy’s intense photoluminescence and X-ray luminescence can be employed for cell imaging, according to the scientists. Details of the crystal structure and optical characteristics of the new complex are slated for publication in an upcoming paper from the Journal of Materials Chemistry. Prof. Chen reported that additional research would include reducing the size of the Cu-Cy nanoparticle to make it more easily absorbed in the tumor tissue. “For cancer, there is still no good solution yet. Hopefully this nanoparticle can provide some possibilities,” he said.

Related Links:

University of Texas at Arlington



comments powered by Disqus

Channels

Genomics/Proteomics

view channel
Image: Differences in the structure of a small lung artery (top row) and heart cross section (lower row) of rodents without disease (far left column); with pulmonary hypertension (middle) and a diseased rodent treated with the HDL peptide (right). Note the much narrowed lung artery, and thick walls and larger chamber of the heart in the diseased animal and improvements with 4F peptide treatment (Photo courtesy of UCLA - University of California, Los Angeles).

Apolipoprotein A-1 Mimetic Peptide Reverses Pulmonary Hypertension in Rodent Models

A small peptide that mimics the activity of apolipoprotein A-1 (apo A-1), the main protein component of the high density lipoproteins (HDL), counteracted the effects of oxidized lipids and alleviated symptoms... Read more

Drug Discovery

view channel
Image: The five stages of biofilm development: (1) Initial attachment, (2) Irreversible attachment, (3) Maturation I, (4) Maturation II, and (5) Dispersion. Each stage of development in the diagram is paired with a photomicrograph of a developing P. aeruginosa biofilm. All photomicrographs are shown to same scale (Photo courtesy of Wikimedia Commons).

Ionic Liquids Disperse Bacterial Biofilms and Increase Antibiotic Susceptibility

The ionic liquid choline-geranate was shown to effectively eliminate the protective biofilm generated by bacteria such as Salmonella enterica and Pseudomonas aeruginosa and to significantly increase the... Read more

Lab Technologies

view channel

Important Immune Cell Regulators’ Response Identified

A new strategy could help accelerate laboratory research and the development of potential therapeutics, including vaccines. The technology may also be used to identify the genes that underlie tumor cell development. There are approximately 40,000 genes in each of the body’s cells, but functions for only approximately... Read more

Business

view channel

Partnership Established to Decode Bowel Disease

23andMe (Mountain View, CA,USA), a personal genetics company, is collaborating with Pfizer, Inc. (New York, NY, USA), in which the companies will seek to enroll 10,000 people with inflammatory bowel disease (IBD) in a research project designed to explore the genetic factors associated with the onset, progression, severity,... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.